- Home
- CLYM
CLYM
CLIMB BIO INC
as 06-18-2025 4:00pm EST
Stocks
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WELLESLEY HILLS |
| Market Cap: | 84.5M | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 196.5K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $9.21 | Next Earning Date: | 08-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest CLIMB BIO INC News
CLYM Breaking Stock News: Dive into CLYM Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
GlobeNewswire
a month ago
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
PR Newswire
a month ago
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB
Exec Edge
2 months ago
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX
GlobeNewswire
3 months ago
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
GlobeNewswire
3 months ago
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
Exec Edge
3 months ago
Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report
Compare CLYM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLYM CLIMB BIO INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.